



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : A61K 31/485, 47/00, 9/70</p>	<p>A1</p>	<p>(11) International Publication Number: WO 92/08459 (43) International Publication Date: 29 May 1992 (29.05.92)</p>																					
<p>(21) International Application Number: PCT/SE91/00760 (22) International Filing Date: 11 November 1991 (11.11.91) (30) Priority data: 9003665-8 16 November 1990 (16.11.90) SE (71) Applicant (for all designated States except US): KABI PHARMACIA AB [SE/SE]; S-751 82 Uppsala (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): BUNDGAARD, Hans [DK/DK]; Tjørnevej 36, DK-2970 Hörsholm (DK). CHRISTRUP, Lona [DK/DK]; Svend Gøngesvej 36, DK-2700 Brønshøj (DK). DRUSTRUP, Jörn [DK/DK]; Hvidkildevej 36 A, DK-2400 København (DK). FULLERTON, Ann [DK/DK]; Grønbakken 5, DK-2720 Vanløse (DK). NICKLASSON, Martin [SE/SE]; Bränningsstrandsvägen 72, S-151 39 Södertälje (SE).</p>		<p>(74) Agents: TANNERFELDT, Agneta et al.; Kabi Pharmacia AB, S-112 87 Stockholm (SE). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), US. Published With international search report.</p>																					
<p>(54) Title: TOPICAL COMPOSITIONS FOR TRANSDERMAL DELIVERY OF PRODUG DERIVATIVES OF MORPHINE</p> <div data-bbox="406 1176 1185 1743"> <table border="1"> <caption>Data points estimated from Graph A</caption> <thead> <tr> <th>Time (h)</th> <th>Amount penetrated (µg/cm²) - Filled Circles</th> <th>Amount penetrated (µg/cm²) - Open Circles</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td>25</td> <td>~50</td> <td>~40</td> </tr> <tr> <td>50</td> <td>~150</td> <td>~100</td> </tr> <tr> <td>75</td> <td>~300</td> <td>~180</td> </tr> <tr> <td>100</td> <td>~480</td> <td>~250</td> </tr> <tr> <td>150</td> <td>~950</td> <td>~350</td> </tr> </tbody> </table> </div> <p>(57) Abstract</p> <p>The invention relates to topical composition for transdermal delivery of morphine. The composition comprises an effective amount of a morphine ester in association with a topical pharmaceutical carrier which gives solutions, suspensions, ointments, lotions, creams, gels, pastes, jellies, sprays and aerosols and/or together with a medical device. The invention also relates to the use of the morphine esters for the manufacture of a topical medicament for transdermal delivery for relieving pain or tranquilizing a mammal.</p>			Time (h)	Amount penetrated (µg/cm²) - Filled Circles	Amount penetrated (µg/cm²) - Open Circles	0	0	0	25	~50	~40	50	~150	~100	75	~300	~180	100	~480	~250	150	~950	~350
Time (h)	Amount penetrated (µg/cm²) - Filled Circles	Amount penetrated (µg/cm²) - Open Circles																					
0	0	0																					
25	~50	~40																					
50	~150	~100																					
75	~300	~180																					
100	~480	~250																					
150	~950	~350																					

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

of penetrating the skin at a sufficiently high rate and are not metabolized during the percutaneous absorption. Morphine which remains the analgesic drug of choice for the treatment of severe pain, unfortunately exhibits, a very limited skin permeability which makes it unsuited for transdermal delivery. For instance, the steady-state flux of morphine through human skin in vitro has been reported to be only 6 ng/cm²/h when applied in the form of a saturated solution (pH 7.4). (Roy, S.D., and Flynn, G.L., Transdermal delivery of narcotic analgesics: comparative permeabilities of narcotic analgesics through human cadaver skin. Pharm. Res. 6 (1989) 825-832). These poor skin-penetration properties of morphine led to the conclusion that morphine is totally unsuited for transdermal delivery. The very poor ability of morphine to permeate into and through the skin can mainly be ascribed to its poor lipophilicity. Thus, the log P value for morphine is only -0.15 where P is the partition coefficient between octanol and aqueous buffer of pH 7.4 (Roy and Flynn 1989). It has now surprisingly been found that transdermal delivery of morphine can be achieved by the prodrug approach proposed in accordance with the present invention.

SUMMARY OF THE INVENTION

The present invention provides novel topical compositions for transdermal delivery comprising an effective amount of a compound represented by the following general Formula I



where R₁ and R₂ are the same or different and are hydrogen and a member selected from the group of physiologically hydrolyzable chemical groups consisting of alkylcarbonyl, alkenylcarbonyl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl and heteroaryloxycarbonyl groups wherein the alkyl moiety consists of unsubstituted or substituted, straight-chain and branched-chain and cyclic alkyl groups having 1-20 carbon atoms, wherein the alkenyl

Topical compositions for transdermal delivery of prodrug derivatives of morphine

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to the use of prodrug derivatives of morphine in effecting transdermal delivery of morphine to the systemic circulation of a mammal.

For purposes of this specification, the term "prodrug" denotes a derivative of morphine which, when administered topically to warm-blooded animals, e. g. humans, is converted into the proven drug, i. e. morphine.

The prodrug forms of morphine of this invention are certain derivatives of morphine which possess a desirable high lipophilicity and biphasic solubility in comparison to the parent compound, morphine, and which are cleaved enzymatically to morphine.

Description of the Prior Art

It is generally known and an accepted practice to administer morphine to control chronic pain. Morphine plays a prominent role in the control of pain associated with chronic diseases, especially the chronic pain of cancer, and acute pain, especially the acute pain experienced post-operatively. However, such prior art uses of morphine are subject to serious problems. In addition to the obvious problems associated with potential abuse and addiction, the oral and parenteral administration of morphine for pain control frequently involve wide swings in the pharmacodynamics of the drug over each dosing interval. Furthermore, morphine has a short duration of action and is inefficiently and variably absorbed orally due to first-pass metabolism in the intestine and liver.

During recent years much attention has been paid to the development of transdermal delivery systems as a means of mitigating many of the drawbacks associated with the parenteral or oral route of administration. (Sloan K B, Adv. Drug Delivery Rev. (1989), 67-101) A prerequisite for the development of a transdermal delivery system of morphine and other opioids is, however, that the drugs are capable

moiety consists of unsubstituted and substituted, straight-chain and branched-chain and cyclic alkenyl groups having 2-20 carbon atoms, wherein the aryl moiety consists of unsubstituted and substituted phenyl, and phenalkyl groups wherein the alkyl moiety contains 1-3 carbon atoms and the phenyl moiety is unsubstituted or substituted, and the heteroaryl moiety is an aromatic 5- or 6-membered heterocyclic ring containing one or two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and nontoxic pharmaceutically acceptable acid addition salts thereof, with the proviso that if $R_1 = \text{hydrogen}$ then $R_2 \neq \text{hydrogen}$, and if $R_2 = \text{hydrogen}$ then $R_1 \neq \text{hydrogen}$

in association with a topical pharmaceutical carrier for solutions, suspensions, ointments, lotions, creams, gels, pastes, jellies, sprays and aerosols and/or together with a medical device.

The invention also provides a composition containing a non-toxic additive acting as a skin penetration enhancer.

Another subject of the invention is topical dosage forms consisting of a matrix type or reservoir type patch system containing a compound as defined in Formula I or this compound in combination with a penetration enhancing delivery device/process such as iontophoresis. Reservoir type patch systems and iontophoresis are both well known systems for transdermal delivery.

The composition according to the invention can also be combined with an additional drug delivery device such as patches, gauze or compresses.

The invention further includes the use of the esters according to Formula I in the manufacture of a topical medicament for transdermal delivery with the intention of for relieving pain or tranquilizing a mammal and the use of these esters for transdermal delivery.

Also claimed is a process for achieving transdermal delivery of morphine, which comprises applying to mammalian skin an effective amount of a composition according to Formula I.

Examples of suitable straight-chain alkyl groups in Formula I include methyl, ethyl, propyl, butyl, hexyl, heptyl, octyl, dodecyl, palmityl and the like groups.

Examples of suitable branched-chain alkyl groups include isopropyl, sec-butyl, t-butyl, 2-methylbutyl, 2-pentyl, 3-pentyl and the like groups.

Examples of suitable cyclic alkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups.

Examples of suitable "alkenyl" groups include vinyl (ethenyl), 1-propenyl, i-butenyl, pentenyl, hexenyl, n-decenyl and c-pentenyl and the like.

The groups may be substituted, generally with 1 or 2 substituents, wherein the substituents are independently selected from halo, hydroxy, alkoxy, amino, mono- and dialkylamino, nitro, carboxyl, alkoxycarbonyl, and cyano groups.

By the expression "phenalkyl groups wherein the alkyl moiety contains 1-3 carbon atoms " is meant benzyl, phenethyl and phenylpropyl groups wherein the phenyl moiety may be substituted. When substituted, the phenyl moiety of the phenalkyl group may contain independently from 1 to 3 alkyl, hydroxy, alkoxy, halo, amino, mono- and dialkylamino, nitro, carboxyl, alkoxycarbonyl and cyano groups.

Examples of suitable "heteroaryl" are pyridinyl, thienyl or imidazolyl.

As noted herein, the expression "halo" is meant in the conventional sense to include F, Cl, Br, and I.

The term "non-toxic pharmaceutically acceptable acid addition salts" as used herein generally includes the non-toxic addition salts of compounds of Formula I, formed with non-toxic inorganic or organic acids. For example, the salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulphuric, sulphamic, nitric, phosphoric and the like; and the salts with organic acids such as acetic, propionic, succinic, fumaric, maleic, tartaric, citric, glycolic, lactic, stearic, malic, pamoic, ascorbic, phenylacetic, benzoic, glutamic, salicylic, sulphanilic, methanesulphonic, and the like.

The inventive method for relieving pain and for tranquilizing mammals comprises the application of the above compositions to mammalian skin and in particular, provides for inducing and maintaining analgesia by administering through an area of intact skin a morphine prodrug of the Formula I at an analgetically effective rate and continuing the administration of said material at said rate for an extended period of time at least sufficient to induce analgesia. Said compositions may contain any type of absorption enhancers, such as fatty acids, fatty acid esters and fatty alcohols as well as any type of pharmaceutical additive commonly used for topical or dermal preparations and/or delivery systems such as transdermal patches. It

is an object of the present invention to provide an improved method of treating and controlling acute and/or chronic pain.

It is a further object of the present invention to enable pain to be controlled over a sustained period of time by administering transdermally a morphine prodrug of Formula I.

According to the present invention, the permeability coefficients and fluxes of the compounds and compositions through mammalian skin tissue are established as being sufficient in magnitude to be practical for direct transdermal applications, producing time-sustained dosage rates consistent for pain suppression and tranquilizing effects over prolonged periods of time.

The morphine prodrug derivatives of the present invention are certain derivatives which show a higher lipophilicity and biphasic solubility than the active parent drug and hence are better able to penetrate the skin of a human or non-human animal and which are capable of reverting to the active morphine during or after transportation through the skin. These characteristics make the derivatives useful for transdermal delivery of morphine.

Figures 1 and 2 show the permeability of some morphine esters through human skin. The amount of morphine appearing in the receptor phase is plotted as a function of time from suspensions or solutions of 3,6-dipropionyl morphine (A), (figure 1) and dihexanoyl morphine (B), (figure 2) in 0.05 M phosphate buffer of pH 7.0 (O) and isopropyl myristate(•).

3,6-Dipropionyl morphine was applied in the form of suspensions in both buffer and IPM whereas 3,6-dihexanoyl morphine was applied in buffer and as a solution (200mg/ml) in IPM.

DETAILED DESCRIPTION OF THE INVENTION

Among the compounds represented by the general Formula I, preferred compounds are such in which R₁ and R₂ are the same and is one of the following groups:

- acetyl
- propionyl
- butyryl
- valeryl
- hexanoyl
- isobutyryl
- methoxyacetyl
- ethoxyacetyl
- benzoyl
- nicotinoyl

methoxycarbonyl
ethoxycarbonyl
propoxycarbonyl
butoxycarbonyl
hexyloxycarbonyl
octyloxycarbonyl
imidazolylcarbonyl

Other preferred compounds are such in which R_1 is hydrogen and R_2 is one of the groups listed above, or R_2 is hydrogen and R_1 is one of these groups.

The compounds of Formula I are esters (carboxylic acid or carbonate esters) of morphine formed either at C_3 or C_6 , or at both hydroxyl groups. Several esters of morphine have long been known including the 3,6-diacetyl ester (heroin) and 3,6-dinicotinoyl ester (nicomorphine). Information on the preparation or pharmacological activity of various esters of morphine can thus be found in the following references: Beckett and Wright (1875), Hesse (1884), Merck (1899), Emde (1930), Mannich and Siewert (1939), Welsh (1954), Zirm and Pongratz (1959), Pongratz and Zirm (1957, 1964), Voldeng et al. (1968), Selmecki et al. (1968), Borowitz and Diakow (1975), May and Jacobsen (1977), Andrew et al. (1984), Owen et al. (1984), Sy et al. (1986), Broekkamp et al. (1988) and Whitehouse et al. (1990). See reference list on page 12.

However, these references or other information in the literature do not disclose or indicate any utility of esters or other derivatives of morphine as prodrug forms suitable for transdermal delivery of morphine, nor any properties of the compounds that might indicate such utility.

As will be described below it has now surprisingly been found that compounds of Formula I - in contrast to morphine itself - are highly useful to achieve transdermal delivery of morphine at an analgetically effective rate and extent.

Preparation of Compounds of Formula I

The compounds of Formula I can be prepared by various methods as already described in the literature for a number of morphine esters (see the references cited above). Thus, we prepared 3,6-dipropionyl, 3,6-diisobutyryl and 3,6-dihexanoyl morphine by reacting morphine with an excess of the corresponding acid anhydride, following the method described by Owen et al.

6-Propionyl morphine was prepared as described by Sy et al. and the 3-propionyl, 3-isobutyryl and 3-hexanoyl esters as described by Welsh.

Detailed descriptions of the preparation of some morphine esters are given in Examples 1-5.

Example 1

3,6-dipropionyl morphine (Formula I, $R_1 = R_2 = C_2H_5CO$)

A mixture of morphine (2.0 g) and propionic anhydride (5.0 ml) was stirred at 90 °C for 4 h. Upon cooling to room temperature water (40 ml) was added. After 1 h the solution was partitioned between ether (50 ml) and 10 % potassium hydroxide solution (40 ml). The ether phase was separated, washed with water, dried over anhydrous sodium sulphate and evaporated in vacuo. The residue obtained was crystallized from ethanol-water to yield 2.7 g of the title compound, m.p. 106-107 °C.

Example 2

3-propionyl morphine (Formula I, $R_1 = C_2H_5CO$, $R_2 = H$)

Propionic anhydride (13.1 ml, 100 mmol) was added while stirring to a mixture of sodium bicarbonate (20 g, 240 mmol) and morphine hydrochloride (3.75g, 10mmol) in water (200 ml). After complete addition the mixture was stirred for 90 min and extracted with chloroform (2 x 100 ml). The combined extracts were dried over anhydrous sodium sulphate and evaporated in vacuo to yield the title compound as a colorless oil in 95% yield. The compound crystallized from petroleum ether at -18°C, m.p. 85-86°C(Anal. : calc./w $C_{20}H_{23}NO_4$: C,70.36; H,6.79; N,4.10. Found: C,70.35; H,6.89, N,4.19.). The hydrochloric acid salt of the compound was prepared by adding a methanolic HCl solution to a solution of the base in ether, m.p. 157-158 °C (monohydrate).

Example 3

3,6-diisobutyryl morphine (Formula I, $R_1 = R_2 = (CH_3)_2CH_2CO$)

The compound was prepared essentially as described in Example 1, using isobutyric anhydride instead of propionic anhydride. The

compound was recrystallized from ether-petroleum ether, m.p. 96-97 °C.

Example 4

3,6-dihexanoyl morphine (Formula I, $R_1 = R_2 = \text{CH}_3(\text{CH}_2)_4\text{CO}$)

The compound was prepared essentially as described in Example 1, using hexanoic anhydride instead of propionic anhydride. The compound was a colorless oil.

Example 5

3-hexanoyl morphine (Formula I, $R_1 = \text{CH}_3(\text{CH}_2)_4\text{CO}$, $R_2 = \text{H}$)

The compound was prepared essentially as described in Example 2, using the equivalent amount of hexanoic anhydride instead of propionic anhydride. The compound was a colorless oil.

Solubility and Lipophilicity of Morphine esters.

The solubility of the compounds, given in Examples 1-5, in water at pH 7 and in isopropyl myristate and their partition coefficients between octanol and pH 7.4 aqueous buffer (P) are shown in Table 1. The experimental methods used for these determinations are described below.

Table 1 Solubilities and partition coefficients (P) of morphine and various ester prodrugs at 21 °C.

Compound	log P ^a	<u>Solubility (mg/ml)</u>	
		In water at pH 7.0	In IPM ^b
Morphine.	-0.06	1.8	0.023
3-Propionyl-morphine	0.66	21	79
3,6-Dipropionyl-morphine	1.66	3.6	41
3-Hexanoyl-morphine	2.04	2.6	>150
3,6-Diisobutyryl-morphine	2.60	0.6	80
3,6-Dihexanoyl-morphine	>4	0.02	>200

a Between octanol and pH 7.4 aqueous buffer.

b IMP: Isopropyl myristate

The solubilities of morphine and morphine esters were determined in triplicate in a phosphate buffer solution of pH 7.0 and in isopropyl myristate (IPM) at 21 °C by placing excess amounts of the compounds in 5 ml of the solvent. The mixtures were placed in an ultrasonic bath for 10 min and then rotated on a mechanical spindle for 24 h and filtered. After rotation for 1 h the pH of the phosphate buffer mixtures was adjusted to 7.0. An aliquot of the filtrates was diluted with water or acetonitrile and analyzed by HPLC.

The apparent partition coefficients (P) of morphine and the various esters were determined at 21 °C in an octanol-0.02 M phosphate buffer (pH 7.4) system. The concentration of the compounds in the aqueous phase before and after partitioning was determined by HPLC analysis, and the partition coefficients determined.

From the data shown in Table 1 it can readily be seen that the morphine esters are more lipophilic than the parent drug in terms of octanol-aqueous buffer partition coefficients. It is also apparent that morphine esters showing both increased water and lipid solubility relative to morphine can be obtained. This higher biphasic solubility may be most favourable for skin penetration.

Skin Permeation Studies.

The feasibility of achieving transdermal delivery of morphine via the prodrugs of the present invention was evaluated by diffusion experiments in vitro using human skin samples.

Whole abdominal human skin obtained under autopsy from two donors was used. The skin was stored at -18 °C and was allowed to thaw gradually at room temperature before use. All subcutaneous fat was removed and the skin cut into pieces. The excised skin was mounted in open Franz diffusion cells. They have an available diffusion area of 0.70 cm².

The dermal side of the skin was exposed to the receptor medium (7.5 ml of 0.05 M isotonic phosphate buffer of pH 7.2) which was stirred magnetically and kept at a constant temperature of 37 °C with a circulating water bath.

The compounds studied were applied as solutions or suspensions (200 microliter) in an aqueous buffer (pH 7.0) or in isopropyl myristate (IPM).

The suspensions were stirred for 24 h prior to application to the skin surface. Samples of 2 ml were removed from the receptor phase and replaced with fresh buffer at appropriate intervals. The samples

were stored at -20 °C until analyzed for their morphine, di- and/or monoester content by HPLC as described below. The permeation studies of each compound were done in tri- or quadruplicate.

Reversed-phase HPLC procedures were used for the quantitative determination of morphine and its esters. A deactivated Supelcosil column was eluted with a mobile phase consisting of a mixture of acetonitrile (15-70 % v/v) and 0.01 M phosphate buffer solution of pH 6.5. The concentration of acetonitrile was adjusted for each compound to give a suitable compound retention time (3-10 min). The flow rate was 1.0 ml/min and the column effluent was monitored at 215 or 280 nm. It was assured that in each case adequate separation of the ester from morphine and monoesters (in the case of the diesters) was achieved. Quantitation of the compounds was done from measurements of the peak heights in relation to those of standards chromatographed under the same conditions.

In the case of morphine no measurable amounts of drug could be detected in the receptor phase during diffusion experiments lasting up to 200 h. The failure of morphine to penetrate human skin from the vehicles applied in significant amounts is in accordance with the results obtained by Roy and Flynn (1989). These authors reported a steady-state flux of $0.006 \mu\text{g}/\text{cm}^2/\text{h}$ for the permeation of morphine through human skin from a saturated solution of the drug in a pH 7.4 buffer.

In contrast, the 3-hexanoyl, 3,6-dihexanoyl and other 3,6-dipropionyl morphine esters readily penetrated human skin. The results obtained with some of these derivatives are shown in Fig. 1 in which the cumulative amounts (in mg morphine base) of morphine or ester measured in the receptor phase divided by the surface area of the diffusion cell are plotted against the time of sampling. The steady-state fluxes were obtained from the slopes of the linear portions of these plots. The permeability coefficients (K_p) for the steady-state delivery were obtained by dividing the steady-state fluxes by the solubilities or concentrations of the compounds in the vehicle applied. The values obtained for various morphine esters, using morphine as a reference, are given in Table 2.

Table 2 Fluxes and permeability coefficients (Kp) for steady-state phase of delivery of morphine through human skin from isopropyl myristate (IPM) and an aqueous buffer of pH 7.0

Compound	Flux($\mu\text{g}/\text{cm}^2/\text{h}$)		Kp(cm/h)	
	IMP	Buffer	IPM	Buffer
Morphine	<0.01	<0.01	$<4.3 \times 10^{-4}$	$<5.6 \times 10^{-6}$
3,6-Dipropionyl-morphine ^a	8.7 ± 0.4	2.5 ± 0.5	3.0×10^{-4}	1.0×10^{-3}
3,6-Dihexanoyl-morphine	11.7 ± 1.2^b	1.7 ± 0.2	$>1.6 \times 10^{-4}$	0.14
3-Hexanoyl-morphine	35.6 ± 12.0^c	25.3 ± 4.2	$>2.4 \times 10^{-4}$	1.3×10^{-2}
3-Propionyl-morphine	37.7 ± 4.1			
3-Acetyl-morphine	11.4 ± 1.8^b			
3-Isobutyryl-morphine	27.0 ± 3.3^b			
3-Valeryl-morphine	16.5 ± 2.7^b			
3-Butoxy-morphine	8.3 ± 2.2^b			

a Approximately 50 % of the amounts penetrated were present in the receptor phase as morphine and 50 % as the 6-monoester. The flux values given were calculated in terms of total morphine equivalents.

b The IPM solution applied was not saturated. It contained the compound at a concentration of 200 mg/ml

c The IPM solution applied was not saturated. It contained the compound at a concentration of 125 mg/ml

For all cases except the 3,6-dipropionyl ester, only morphine was found in the receptor phase, whereas for the 3,6-dipropionyl ester approximately 50 % of the amounts penetrated were present in the receptor phase as morphine and 50 % as the corresponding 6-monoester. It is of great interest to note the appreciable skin enzyme-mediated hydrolysis of the esters during diffusion.

An experiment with 3-Propionyl-morphine dissolved in ethanol-water (3:1 vol/vol) at a concentration of 620 mg/ml revealed a flux of $102 \pm 8.0 \mu\text{g}/\text{cm}^2/\text{h}$.

The results obtained from the human skin permeation experiments show that it is possible to a very high degree improve the skin penetration of morphine via prodrugs. Thus, the 3-hexanoyl ester afforded a more than 2,000-fold higher flux relative to morphine itself when delivered from an aqueous buffer vehicle, and progressively greater enhancement was achieved when isopropyl myristate was used as a vehicle. The increased solubility of the esters in the vehicles (Table 1) combined with expected concomitant

example, for transdermal delivery is 25 cm^2 and if a flux of 25 microgram/h/cm² is used (see Table 2), it would be possible to deliver 0.625 mg morphine/h or 15 mg over 24 h. This amount is higher than that usually administered (10 mg) parenterally during 24 hours.

The actual administration or use of the transdermal analgesic compositions according to the present invention can be in any conventional form and may follow any of the methods generally known to the art. For instance, the active narcotic analgetic compound (i.e., a morphine prodrug of Formula I) can be used in association with any pharmaceutical dosage form such as, for example, but not limited thereto, any solution, ointment, lotion, paste, jelly, gel, cream, spray or aerosol generally known to the art. As such, the narcotic analgetic prodrug form in association with the pharmaceutical dosage form can be used directly as a topical composition or used in combination with an additional drug delivery device, for example, but not limited thereto, patches, gauze, compresses, or the like, again, as generally known in the art. The dosage forms may contain any type of absorption enhancers such as fatty acids, fatty acid esters and fatty alcohols or any other non-toxic compounds which are known to increase skin permeability. In particular, the transdermal analgesic compositions can be administered in the form of a patch wherein the active morphine prodrug agent is present in a polymeric matrix or in a reservoir system combined with a polymeric rate controlling membrane.

Reference list

Andrew, R., Tasker, R. and Nakatsu, K.
Evaluation of 3,6-dibutanoylmorphine as an analgesic in vivo:
comparison with morphine and 3,6-diacetyl morphine.
Life Sci. 34 (1984) 1659-1667

Beckett, G.H. and Wright, C.R.A.,
Action of the organic acids and their anhydrides on the natural
alkaloids. Part II.
J. Chem. Soc. 28 (1875) 15-26

Borowitz, I.J. and Diakiw, V.,
The preparation and synthetic utility of 0-substituted
normethylmorphines.
J. Heterocycl. Chem., 12 (1975) 1123-1126.

Broekkamp, C.L., Oosterloo, S.K. and Rijk, H.W.,
Prodrug behaviour of nicotinoylmorphine esters.
J. Pharm. Pharmacol. 40 (1988) 434-437.

Emde, H.,
Über Diastereomerie VI. Konfiguration der Morphinalkaloide.
Helv. Chim. Acta, 13 (1930) 1035-1058.

Hesse, O.,
Studien über Morphin.
Ann. Chem., 222 (1884) 203-234.

Mannich, C. and Siewert, G., Über 6-Benzoyl-morphin.
Arch. Pharm., 277 (1939) 128-130.

May, E.L. and Jackson, A.E.,
Chemistry and pharmacology of homologs of 6-acetyl and 3,6-
diacetylmorphine.
J. Pharm. Sci., 66 (1977) 285-286.

Merck, E.,
Ueber einige Morphinderivate.
Arch. Pharm., 237 (1899) 211-222.

Owen, J.A., Elliott, J., Jhamandas, K., and Nakatsu, K.,
Morphine diesters, I. Synthesis and action on guinea pig ileum.

Can. J. Physiol. Pharmacol., 62 (1984) 446-451.

Pongratz, A. and Zirm, K.L.,
Verfahren zur Darstellung des neuen 6-Morphin
Mononicotinsaureesters.
Osterr. Patentschrift Nr. 234,914 (1964).

Pongratz, A. and Zirm, K.L.,
Monatsh., 88 (1957) 330.

Selmeci, G., Szlavik, L., Kaskoto, Z., Lepenyene, J.M. and Tothne, A.I.,
Synthesis of new derivatives of morphine. II. Production of
benzoylmorphines with analgesic action and benzylmorphine
possessing morphine-potentiating activity.
Khim. Farm. Zh., 2 (7) (1968) 19-23

Sy, W.-W., By, A.W., Neville, G.A. and Wilson, W.L.,
Syntheses of 3-O- and 6-O-propanoylmorphine - a reinvestigation and
correction.
J. Pharm. Sci., 75 (1986) 787-789.

Voldeng, A.N., Brandley, A., Kee, R.D., King, E.L. and Melder, F.L.,
Synthesis of adamantyl analogs of analgesics.
J. Pharm. Sci., 57 (1968) 1053-1055.


Welsh, L.H.,
O3-Monoacetylmorphine.
J. Org. Chem., 19 (1954) 1409-1415.

Whitehouse, L.W., Paul, C.J., Gottschling, K.H., Lodge, B.A. and By, A.W.,
Antinociceptive activity of propionyl esters of morphine: a
reevaluation.
J. Pharm. Sci., 79 (1990) 349-350.

Zirm, K.L. and Pongratz, A.,
Zur Wirkung des Pyridin-3-Carbonsäurebiesters des Morphines als
Analgeticum.
Arzneim.-Forsch., 9 (1959) 511-513.

CLAIMS

1. A topical composition for transdermal delivery of morphine comprising an effective amount of a compound of the formula:



wherein R₁ and R₂ are the same or different and are hydrogen and a member selected from the group of physiologically hydrolyzable chemical groups consisting of alkylcarbonyl, alkenylcarbonyl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxy carbonyl and heteroaryloxy carbonyl groups wherein the alkyl moiety consists of unsubstituted and substituted, straight-chain and branched-chain and cyclic alkyl groups having 1-20 carbon atoms, wherein the alkenyl moiety consists of unsubstituted and substituted, straight-chain and branched-chain and cyclic alkenyl groups having 2-20 carbon atoms, wherein the aryl moiety consists of unsubstituted and substituted phenyl, and phenalkyl groups wherein the alkyl moiety contains 1-3 carbon atoms and the phenyl moiety is unsubstituted or substituted, and the heteroaryl moiety is an aromatic 5- or 6-membered heterocyclic ring containing one or two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and nontoxic pharmaceutically acceptable acid addition salts thereof, with the proviso that if R₁ = hydrogen then R₂ ≠ hydrogen, and if R₂ = hydrogen then R₁ ≠ hydrogen

in association with a topical pharmaceutical carrier which gives solutions, suspensions, ointments, lotions, creams, gels, pastes, jellies, sprays and aerosols and/or together with a medical device.

2. A composition according to Claim 1 wherein R_1 and R_2 each are acetyl, propionyl, butyryl, isobutyryl, valeryl, hexanoyl, octanoyl, ethoxyacetyl, methoxycarbonyl, ethoxycarbonyl, or benzoyl.

3. A composition according to Claim 2 wherein R_1 is hydrogen and R_2 is as claimed in Claim 2.

4. A composition according to Claim 2 wherein R_2 is hydrogen and R_1 is as claimed in Claim 2.

5. A composition according to any of claims 1-4 containing a non-toxic additive acting as a skin penetration enhancer.

6. A topical dosage form consisting of a matrix type or reservoir type patch system containing a compound according to Formula I as defined in claim 1.

7. A topical dosage form consisting of a compound according to Formula I as defined in claim 1 in combination with a penetration enhancing delivery device/process such as iontophoresis.

8. A topical dosage form in which the composition according to any of claims 1-4 is combined with an additional drug delivery device such as patches, gauze or compresses.


9. Use of the esters according to Formula I in as defined in claim 1 for the manufacture of a topical medicament for transdermal delivery for relieving pain or tranquilizing a mammal.

10. Use of the esters according to Formula I as defined in claim 1 for transdermal delivery.

11. A process for achieving transdermal delivery of morphine comprising the application to mammalian skin of an effective amount of a composition according to any of claims 1-4.


1 / 2

Figure 1






2 / 2

Figure 2



INTERNATIONAL SEARCH REPORT

International Application No PCT/SE 91/00760

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: A 61 K 31/485, 47/00, 9/70																	
II. FIELDS SEARCHED <div style="text-align: center;">Minimum Documentation Searched⁷</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%;">Classification System</th> <th style="width: 75%;">Classification Symbols</th> </tr> <tr> <td style="height: 40px; vertical-align: bottom;">IPC5</td> <td style="vertical-align: bottom;">A 61 K</td> </tr> </table> <div style="text-align: center;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in Fields Searched⁸</div> <p>SE,DK,FI,NO classes as above</p>			Classification System	Classification Symbols	IPC5	A 61 K											
Classification System	Classification Symbols																
IPC5	A 61 K																
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category *</th> <th style="width: 60%;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 30%;">Relevant to Claim No.¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td style="vertical-align: top;">EP, A2, 0171742 (E.I. DU PONT DE NEMOURS AND COMPANY) 19 February 1986, see the whole document --</td> <td style="text-align: center; vertical-align: top;">1-10</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A,P</td> <td style="vertical-align: top;">WO, A1, 9115241 (MORIMOTO, Y) 17 October 1991, see the whole document --</td> <td style="text-align: center; vertical-align: top;">1-10</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td style="vertical-align: top;">Pharmaceutical Research, Vol. 6, No. 10, 1989 Samir D. Roy et al.: "Transdermal Delivery of Narcotic Analgesics: comparative Permeabilities of Narcotic Analgesics Through Human Cadaver Skin", see page 825 - page 832 ---</td> <td style="text-align: center; vertical-align: top;">1-10</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td style="vertical-align: top;">Chemical Abstracts, volume 112, no. 10, 5 March 1990, (Columbus, Ohio, US), Rieg-Falson, F. et al.: "Characterization of the enhancing effect of a vehicle in a transdermal system ", see page 433, abstract 84017c, & Drug. Dev. Ind. Pharm. 1989, 15(14), 2393-2406 ---</td> <td style="text-align: center; vertical-align: top;">1-10</td> </tr> </tbody> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	EP, A2, 0171742 (E.I. DU PONT DE NEMOURS AND COMPANY) 19 February 1986, see the whole document --	1-10	A,P	WO, A1, 9115241 (MORIMOTO, Y) 17 October 1991, see the whole document --	1-10	A	Pharmaceutical Research, Vol. 6, No. 10, 1989 Samir D. Roy et al.: "Transdermal Delivery of Narcotic Analgesics: comparative Permeabilities of Narcotic Analgesics Through Human Cadaver Skin", see page 825 - page 832 ---	1-10	A	Chemical Abstracts, volume 112, no. 10, 5 March 1990, (Columbus, Ohio, US), Rieg-Falson, F. et al.: "Characterization of the enhancing effect of a vehicle in a transdermal system ", see page 433, abstract 84017c, & Drug. Dev. Ind. Pharm. 1989, 15(14), 2393-2406 ---	1-10
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
A	EP, A2, 0171742 (E.I. DU PONT DE NEMOURS AND COMPANY) 19 February 1986, see the whole document --	1-10															
A,P	WO, A1, 9115241 (MORIMOTO, Y) 17 October 1991, see the whole document --	1-10															
A	Pharmaceutical Research, Vol. 6, No. 10, 1989 Samir D. Roy et al.: "Transdermal Delivery of Narcotic Analgesics: comparative Permeabilities of Narcotic Analgesics Through Human Cadaver Skin", see page 825 - page 832 ---	1-10															
A	Chemical Abstracts, volume 112, no. 10, 5 March 1990, (Columbus, Ohio, US), Rieg-Falson, F. et al.: "Characterization of the enhancing effect of a vehicle in a transdermal system ", see page 433, abstract 84017c, & Drug. Dev. Ind. Pharm. 1989, 15(14), 2393-2406 ---	1-10															
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents:¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>																	
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> Date of the Actual Completion of the International Search 7th February 1992 </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report 1992 -02- 12 </td> </tr> <tr> <td style="width: 50%; padding: 5px;"> International Searching Authority <div style="text-align: center;">SWEDISH PATENT OFFICE</div> </td> <td style="width: 50%; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center;">  Eva Johansson </div> </td> </tr> </table>			Date of the Actual Completion of the International Search 7th February 1992	Date of Mailing of this International Search Report 1992 -02- 12	International Searching Authority <div style="text-align: center;">SWEDISH PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">  Eva Johansson </div>											
Date of the Actual Completion of the International Search 7th February 1992	Date of Mailing of this International Search Report 1992 -02- 12																
International Searching Authority <div style="text-align: center;">SWEDISH PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">  Eva Johansson </div>																

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers.....11., because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. ☐ Claim numbers....., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the the claims. It is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.PCT/SE 91/00760

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the Swedish Patent Office EDP file on 30/11/91
The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0171742	86-02-19	AU-B- 574628	88-07-07
		AU-D- 4590585	86-02-13
		JP-A- 61083116	86-04-26
		US-A- 4626539	86-12-02

WO-A1- 9115241	91-10-17	NONE	